SOUTH EASTON, Mass. – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the official opening of its new Ultra Shear Technology™️ (“UST™️”) Demonstration Laboratory (the “UST Demo Lab”). The UST Demo Lab is located in the Company’s South Easton, Massachusetts facility.
A major purpose of the UST Demo Lab is to showcase the ability of the Company’s revolutionary UST Platform to process CBD oil into true, high quality, water-soluble nanoemulsions. It is expected that nanoemulsions of CBD will be more stable, have superior aesthetic quality, and offer higher bioavailability than the standard macro/microemulsions used in most CBD products today (Nanoemulsions, in Handbook of Nanomaterials in Industrial Applications, Ghodake and Patravale, 2018). A second purpose is to invite potential purchasers of the Company’s UST-based BaroShear Systems (initial release expected Q4 2020) to evaluate how their CBD and other product formulations work with the Company’s revolutionary UST platform.
This Company today released a new short video demonstrating how CBD oil from an independent manufacturer was processed into a clear, water-soluble nanoemulsion using a UST-based, first generation BaroShear system. The video shows the CBD oil and water mixture prior to and after UST processing.
CBD and other cannabinoids are extracted from the hemp plant in an oil form. The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from ingested or topically applied hemp oil drops. According to Jason Ellis, President of Vegas CBD Factory, “My colleagues in the cannabis market are beginning to realize that high quality CBD products will only come by using high quality, water-soluble nanoemulsions of CBD oil, such as those generated from processing CBD Oil with PBI’s UST™️ platform, which I have observed first-hand in their lab.”
Kenneth F. Micciche, Director of PBI’s UST Program, said: “We processed samples of CBD oil formulations from several highly interested companies over the past two months, in an effort to optimize the service we are announcing today. The results speak for themselves: one group (Vegas CBD Factory) ordered six BaroShear K45 systems (for Q4 2020 delivery and installation), while we believe several more companies are close to giving us their purchase orders. The ability to showcase the UST platform in motion, and see the final product first-hand, has been shown to be vital to our marketing efforts. As has been said in the past: ‘show it and they will come’. This is a very important accomplishment in our UST sales and marketing strategy.”
Richard T. Schumacher, President and CEO of PBI commented: “The initial reactions from manufacturers of topical and ingestible cannabidiol products tested in our lab during the trial period have been extremely positive. They quickly saw how they could realize substantial cost reductions while eliminating the overloading of poorly water-soluble CBD and other cannabinoids into products to achieve targeted dosing levels. We believe our breakthrough technology platform provides them with a new-found ability to provide safe and effective dosing for their customers, which in turn should stimulate greater growth in the market for CBD-based products overall, and strong sales of our BaroShear product line when it is released to the market later this year.”
About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.